Aubin Henri-Jean, Ali Oicheih Laetitia, Gabriel Sonia, Berlin Ivan
Département de psychiatrie et d'addictologie, Hopital Paul Brousse, Villejuif, Île-de-France, France
CESP, INSERM, Université Paris-Saclay, Villejuif, Île-de-France, France.
BMJ Open. 2021 Jan 20;11(1):e039483. doi: 10.1136/bmjopen-2020-039483.
Strong evidence shows that smoking cessation decreases mortality. Much less is known regarding the association between reduction in cigarettes per day (CPD) and mortality. The primary aim of this systematic review is to compare the mortality risk between smokers achieving a sustained reduction of CPD and smokers maintaining their smoking rate. The secondary aims are to compare the mortality risk between smokers achieving complete, sustained smoking cessation and (1) smokers maintaining their smoking rate and (2) smokers who achieved a sustained reduction in smoking rate.
MEDLINE, Web of Sciences and Embase will be searched using a prespecified search strategy, up to 23 November 2020, and will be limited to studies published in English and in French. Longitudinal observational studies using individual data including smokers with at least two distant CPD assessments and a follow-up period of systematic mortality data recording will be included. The main outcome will be the all-cause mortality. The secondary outcome will be specific mortality. The Newcastle-Ottawa Scale will be used to assess the risk of bias of individual studies. Outcomes will be analysed using HRs. All other outcomes' effect size reported in included studies will be converted in HRs using validated methods.
We intend to publish the results of our review in a peer-reviewed journal and to present the findings at national and international meetings and conferences.
CRD42019138354.
有力证据表明戒烟可降低死亡率。关于每日吸烟量（CPD）减少与死亡率之间的关联，人们了解得要少得多。本系统评价的主要目的是比较实现CPD持续减少的吸烟者与维持吸烟率的吸烟者之间的死亡风险。次要目的是比较实现完全、持续戒烟的吸烟者与（1）维持吸烟率的吸烟者以及（2）实现吸烟率持续降低的吸烟者之间的死亡风险。
将使用预先指定的检索策略检索MEDLINE、科学网和Embase，检索截至2020年11月23日，并将检索范围限制为以英文和法文发表的研究。将纳入使用个体数据的纵向观察性研究，包括至少有两次不同CPD评估且有系统死亡率数据记录随访期的吸烟者。主要结局将是全因死亡率。次要结局将是特定死亡率。将使用纽卡斯尔-渥太华量表评估个体研究的偏倚风险。将使用风险比（HRs）分析结局。纳入研究中报告的所有其他结局的效应量将使用经过验证的方法转换为HRs。
我们打算在同行评审期刊上发表我们的综述结果，并在国内和国际会议上展示研究结果。
PROSPERO注册号：CRD42019138354。
